CC
NVCR icon

Centiva Capital’s NovoCure NVCR Stock Holding History

Centiva Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,708
Closed -$214K – 2178
2024
Q3 		$214K Buy
+13,708
New +$249K ﹤0.01% 1777
2024
Q2 		– Sell
-13,141
Closed -$205K – 2377
2024
Q1 		$205K Sell
13,141
-17,331
-57% -$255K 0.01% 1465
2023
Q4 		$455K Sell
30,472
-20,936
-41% -$280K 0.01% 1006
2023
Q3 		$830K Buy
+51,408
New +$1.48M 0.02% 731
2022
Q3 		– Sell
-7,045
Closed -$490K – 1722
2022
Q2 		$490K Buy
+7,045
New +$531K 0.01% 927
2021
Q3 		– Sell
-1,914
Closed -$425K – 1516
2021
Q2 		$425K Buy
+1,914
New +$372K 0.01% 893

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centiva Capital's NVCR Position: Q4 2024 in Review

Centiva Capital sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 13,708 shares — an estimated $214K sold.

Centiva Capital first reported a position in NVCR in Q2 2021 and held it in 6 quarters. The position peaked at $830K in Q3 2023. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Centiva Capital reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 13,708 NovoCure shares in Q4 2024, an estimated $214K.
  • Centiva Capital first reported a position in NovoCure in Q2 2021 and held it in 6 quarters.
  • Centiva Capital's NovoCure position peaked at $830K in Q3 2023.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.